The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Cynthia X MaJingqin R LuoRachel A FreedmanTimothy J PluardJulie R NangiaJanice LuFrances Valdez-AlbiniMelody CobleighJason M JonesNancy U LinEric P WinerP Kelly MarcomShana ThomasJill AndersonBrittney HaasLeslie BucheitRichard BryceAlshad S LalaniLisa Anne CareyMatthew P GoetzFeng GaoGretchen KimmickMark D PegramMatthew J EllisRon BosePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Neratinib and fulvestrant are active for ER+/HER2mut MBC. Our data support further evaluation of dual HER2 blockade for the treatment of HER2mut MBC.